The software provides patient-facing instructions within a clinician-defined care plan, enabling medication titration and related care coordination tasks, sources said. Unlike prior AI-cleared devices that primarily analyze medical images or flag anomalies, UpDoc V1.0 incorporates a large language model (LLM) directly in a patient-facing workflow, marking a regulatory first in this category.

The UpDoc V1.0 device, cleared under FDA 510(k) number K253281 on December 23, 2025, is designed to support insulin and medication management for adults with type 2 diabetes, operating under licensed clinician supervision, according to company officials and public FDA records.

UpDoc framed the clearance as a significant milestone for patient-facing LLMs in regulated medical software, with the device’s scope narrowly defined to specific clinical tasks consistent with the FDA’s substantial equivalence review process under the 510(k) pathway, company statements and regulatory analysis show. The predicate device cited for this clearance was the non-LLM d-Nav system, which also supports diabetes medication management, sources confirmed. The company emphasized that UpDoc V1.0 does not independently make treatment decisions but functions within protocol-bounded, clinician-supervised parameters.

The FDA’s clearance did not require a traditional clinical trial, according to reporting on the submission process. Instead, the company provided design controls, clinical evidence, and a Predetermined Change Control Plan (PCCP) to address the device’s total product life cycle, as outlined in FDA guidance documents on AI and machine learning-enabled medical devices. The FDA has indicated it is exploring ways to identify and tag devices incorporating foundation models, including LLMs, in its regulatory framework, according to agency materials.

UpDoc announced the clearance alongside news of an $18 million seed funding round, which included participation from Mayo Clinic and Eli Lilly, industry sources reported. The company is positioning itself as an enterprise-ready clinical AI firm, focusing on real-time patient care and care coordination, with initial deployment discussions reportedly targeted at major health systems. This strategic approach aligns with the device’s narrowly scoped clinical application and supervised use model.

Regulatory experts note that the classification of software as a medical device depends heavily on the software’s intended use, particularly whether it provides specific diagnostic or treatment directives. UpDoc’s platform, by operating under licensed clinician oversight and within defined protocols, fits within existing FDA pathways for SaMD, according to regulatory commentary. This approach contrasts with open-ended conversational assistants, which pose greater regulatory challenges due to potential risks associated with autonomous clinical decision-making.

Most AI/ML medical devices cleared by the FDA to date have been authorized through the 510(k) pathway rather than De Novo or premarket approval (PMA), with estimates suggesting that approximately 97% of cleared AI/ML devices as of late 2023 used 510(k) clearance, according to secondary analyses cited in industry reporting. The UpDoc device’s clearance exemplifies how tightly bounded, clinician-supervised AI tools can meet regulatory requirements without extensive clinical trials.

Academic research highlights that LLMs can produce outputs resembling medical device functions even when constrained to decision-support roles, underscoring the FDA’s emphasis on transparency, human oversight, and safety in regulating patient-facing AI tools. The agency’s AI-enabled medical device webpage states ongoing efforts to refine identification and oversight methods for devices incorporating foundation models.

UpDoc’s clearance represents a step in the evolving regulatory landscape for AI-enabled medical devices, with the FDA continuing to develop policies that address the unique challenges posed by foundation models and large language models in healthcare settings.

The agency upgraded the recall to a Class I designation on July 1, 2026, signifying the highest risk level, due to the potential presence of salmonella in a seasoning ingredient containing dry milk powder. The seasoning, supplied by California Dairies, tested negative for salmonella before use, but Utz initiated the voluntary recall in May 2026 “out of an abundance of caution,” officials said. No illnesses have been reported to date in connection with the recalled products, according to FDA statements.

The recall affects over 650,000 bags of Zapp’s and Dirty brand potato chips sold nationwide, according to the FDA and Utz Quality Foods, a subsidiary of Utz Brands.

The affected products include several flavors under both the Zapp’s and Dirty brands, such as Zapp’s Bayou Blackened Ranch, with “Best By” dates in August 2026, as detailed in the FDA recall notice. Retailers nationwide were instructed to remove these products from store shelves immediately, and consumers are urged not to consume the chips and to dispose of them, Utz Customer Care representatives said. The company has made a customer service line available at 1-877-423-0149 for inquiries and refunds.

Separately, the FDA also elevated the recall of over 6,300 bags of Lay’s 13-ounce Classic Potato Chips to Class I due to the risk of serious allergic reactions from undeclared milk. This recall, initiated by Frito-Lay on December 16, 2024, affects products distributed exclusively in Oregon and Washington. The affected Lay’s Classic chips were available for purchase starting November 3, 2024, at select retail stores and e-commerce distributors, according to FDA records and company disclosures. The recall is limited to this specific product and size; no other Lay’s flavors, sizes, or variety packs are involved, Frito-Lay officials confirmed.

The undeclared milk in the Lay’s Classic chips poses a risk of life-threatening allergic reactions for individuals with milk allergies or severe sensitivities, the FDA said. No allergic reactions have been reported in connection with this recall, according to Frito-Lay and FDA reports. Consumers with affected products are advised to stop consumption and discard the chips immediately. Frito-Lay has established a consumer relations line at 1-800-352-4477 for questions about the recall.

The FDA’s Class I classification indicates a reasonable probability that use of the recalled products could cause serious adverse health consequences or death. The salmonella risk associated with the Utz-related recall is considered particularly serious because salmonella infections can cause severe illness, especially in vulnerable populations such as young children, the elderly, and those with weakened immune systems, according to FDA health advisories and media reports. The agency’s decision to upgrade the Utz recall to Class I came approximately two months after the initial voluntary recall was announced.

The recall of the Utz products reflects a nationwide concern, while the Frito-Lay recall is geographically limited to the Pacific Northwest. Consumers are encouraged to verify if their products are affected by checking “Best By” dates and batch codes listed in the FDA recall notices for each brand. Both companies are cooperating with the FDA and have removed the recalled products from the market, officials said.

The FDA continues to monitor the situation and advises consumers to remain vigilant regarding product recalls involving potential contamination or undeclared allergens. The agency’s classification system is designed to prioritize public health risks, with Class I recalls representing the most urgent warnings requiring immediate consumer action.

The supplemental New Drug Application (sNDA) accepted by the FDA seeks to extend the use of dolutegravir, marketed as Tivicay PD, to newborns from birth, expanding the current indication that covers pediatric patients aged at least four weeks and weighing 3 kilograms or more, according to a June 22, 2026, press release from ViiV Healthcare. Tivicay PD is a pediatric formulation consisting of tablets for oral suspension, designed to meet the dosing needs of very young infants and children, the company noted.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of August 25, 2026, for this review, officials said.

Previously, Tivicay and Tivicay PD were approved for use in pediatric patients four weeks and older, including those who are treatment-naive or treatment-experienced but integrase strand transfer inhibitor (INSTI)-naive, according to FDA records and U.S. Department of Health and Human Services (HHS) HIV treatment guidelines. The new application aims to lower the age limit to include neonates in the first days of life, a move that would allow earlier initiation of antiretroviral therapy (ART) in infants diagnosed with HIV at birth.

The priority review designation follows extensive clinical and pharmacokinetic data supporting the safety and dosing of dolutegravir in neonates. Published case reports and population pharmacokinetic modeling indicate that neonatal dosing requirements vary depending on maternal dolutegravir exposure prior to delivery, officials said. Transplacental transfer of the drug affects neonatal drug levels, necessitating weight-band and age-specific dosing to maintain therapeutic concentrations while avoiding toxicity, according to pharmacokinetic analyses cited in the FDA briefing documents. These findings underscore the need for a dedicated newborn indication to optimize treatment protocols.

Safety considerations remain a critical aspect of the review. Data from an NIH-funded observational study in Botswana suggested a possible increased risk of neural tube defects in infants born to women who received dolutegravir at conception, according to published studies and FDA safety communications. Ongoing observational studies cited by the FDA reaffirm this association but note that further analyses are needed to confirm the signal. U.S. pediatric HIV guidelines recommend that providers discuss this potential risk with adolescents and caregivers when initiating dolutegravir in patients of childbearing potential. However, the safety concerns pertain to maternal periconception exposure and not to dolutegravir use in newborns after birth, officials clarified. Despite these findings, dolutegravir-based regimens remain preferred options for children weighing 25 kilograms or more, reflecting their favorable efficacy and safety profiles when used appropriately.

ViiV Healthcare, described in its press release as the global specialist HIV company majority-owned by GlaxoSmithKline with Shionogi as a shareholder, is the sponsor of Tivicay PD. The company provided media contacts Kate Senter in London and Melinda Stubbee in North Carolina for inquiries related to the announcement. The FDA previously communicated the pediatric approval of Tivicay and Tivicay PD for children aged four weeks and older through a press release listing Alison Hunt as the media contact and the “888-INFO-FDA” line for consumer information.

The proposed extension of dolutegravir use to neonates aligns with U.S. pediatric HIV treatment guidelines, which recommend initiating ART in all treatment-naive infants and children with HIV infection, with rapid initiation within one to two weeks for young infants or those with advanced disease, according to HHS clinical guidelines. Dolutegravir combined with two nucleoside reverse transcriptase inhibitors is classified as a preferred INSTI-based regimen for children weighing 25 kilograms or more. The expansion to newborns would facilitate earlier treatment initiation, potentially improving virologic control and reducing the HIV reservoir size in infants, researchers have noted.

Population pharmacokinetic studies emphasize the importance of accounting for maternal dolutegravir exposure when determining neonatal dosing, which has implications for clinical protocols in labor and delivery settings and early infant HIV services. This regulatory development in the United States may influence updates to World Health Organization and national guidelines, supporting broader global adoption of dolutegravir-based regimens for infants once safety, dosing, and implementation issues are fully addressed, according to experts in pediatric HIV treatment.

The FDA’s upcoming decision on the sNDA will be closely watched by clinicians and public health officials, as extending access to potent antiretroviral therapy from birth could have significant implications for the management of HIV in newborns, particularly in regions with high maternal HIV prevalence.

Officials across the country urged caution as a record-setting heat wave affected Fourth of July celebrations nationwide. The National Weather Service (NWS) warned that extreme heat could pose serious health risks, particularly during outdoor gatherings over the holiday weekend. The agency advised residents to stay hydrated by drinking plenty of water throughout the day, even if they do not feel thirsty, and to take hourly breaks in shaded or air-conditioned areas when spending extended time outdoors, according to a July 4 report from Al Jazeera.

Health authorities emphasized the importance of monitoring vulnerable populations, including seniors, pregnant women, children, people living alone, outdoor workers, and athletes.

Los Angeles County public health officials specifically urged residents to check on family, friends, and neighbors at risk for heat-related illness. The county listed symptoms of heat stroke as high body temperature, vomiting, dizziness, confusion, and hot, red, dry, or damp skin, calling heat stroke a medical emergency that requires immediate attention and advising calling 911 if symptoms worsen or body temperature reaches 103 degrees Fahrenheit or higher.

The Centers for Disease Control and Prevention (CDC) recommended spending time in air-conditioned environments at home or in public places to prevent heat-related illness. Additional guidance from the CDC included wearing loose-fitting clothing and taking cool showers or baths. The National Park Service also issued safety instructions for visitors attending events like the National Mall Fourth of July celebration, advising frequent breaks in the shade and access to air conditioning, especially between 10 a.m. and 3 p.m. Visitors were encouraged to bring water bottles and drink regularly, even when not feeling thirsty.

Officials cautioned against consuming alcohol during prolonged outdoor activities in extreme heat. The NWS and public health agencies discouraged heavy drinking, noting that alcohol can worsen dehydration. The National Park Service advised minimizing beverages containing caffeine or alcohol at the National Mall celebration, while Los Angeles County public health warned against drinks that increase fluid loss. NBC Washington’s heat guidance similarly recommended drinking water instead of alcohol or sugary beverages.

Local and regional governments issued event-day safety instructions to help residents cope with the heat. In New York City, Mayor Zohran Mamdani urged people to stay indoors to avoid “extraordinary temperatures” and asked residents to set air conditioners to 78 degrees Fahrenheit (26 degrees Celsius) to reduce strain on the power grid. In Missouri, the State Emergency Management Agency advised residents to plan accordingly and limit prolonged outdoor exposure if possible, emphasizing the need to take immediate action if signs of heat-related illness appear.

The heat wave, described by KPBS as a “heat dome,” was forecast to blanket much of the United States through the July 4 weekend. Records showed that large portions of the central and eastern U.S. were experiencing record-breaking temperatures, according to reports from The Economic Times citing the Associated Press and the NWS. USA Today reported on July 4 that the extreme heat was affecting celebrations nationwide, with health officials warning that fireworks and outdoor festivities could be dangerous under the conditions. WSET also covered warnings from health officials about the combined risks of heat and holiday activities.

The Red Cross issued Independence Day heat safety guidance, reflecting broader concern about exposure risks during holiday events. NBC Washington advised pet owners to keep animals inside and limit outdoor walks to early morning hours with water breaks as needed. Public health agencies stressed the importance of protecting vulnerable groups and encouraged community members to remain vigilant throughout the heat wave.

As the holiday weekend continued, officials maintained that the extreme heat conditions demanded heightened awareness and preventive measures to reduce the risk of heat-related illnesses and emergencies.

The outbreak involves an extensively drug-resistant strain of Salmonella, which has complicated treatment efforts, federal officials said. The outbreak was initially linked to Rosabella brand moringa powder capsules, produced by Ambrosia Brands, LLC, following a recall issued on February 13, 2026.

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have reported 119 illnesses across 36 states, including 32 hospitalizations, with no deaths confirmed as of April 2026.

The investigation had been closed in March 2026 after the initial recall, but new information prompted the FDA and CDC to reopen the case. According to FDA records and a Food Safety News report, 22 additional illnesses from four states were identified during the reopened investigation, expanding the scope of the outbreak. The FDA and CDC continue to trace and sample products while issuing public advisories to consumers and retailers.

The recalled Rosabella moringa powder capsules were found to be contaminated with Salmonella and were distributed nationwide and internationally, the FDA said. Consumers and retailers have been urged to check lot codes and not to consume, sell, or distribute any recalled lots. The FDA advises anyone with the product to discard or return it. The agency also recommends cleaning and sanitizing surfaces and containers that may have come into contact with the recalled capsules to prevent cross-contamination.

The CDC has warned that Salmonella infections can cause serious illness, especially in young children, older adults, and people with weakened immune systems. Symptoms include diarrhea accompanied by fever, bloody diarrhea, vomiting that prevents drinking fluids, and signs of dehydration. The CDC advises anyone experiencing these symptoms to seek medical attention promptly. The FDA has also encouraged healthcare providers and consumers to report any adverse events related to the recalled products through its MedWatch program.

The outbreak is part of a broader pattern of Salmonella cases linked to moringa leaf powder products in 2026. An earlier FDA investigation documented 11 cases across seven states in October 2025, with three hospitalizations and no deaths, but the contamination source was not identified at that time. Another 2026 outbreak involved 18 illnesses across 14 states, indicating multiple moringa-related Salmonella events in the same year, according to public health reports.

The FDA and CDC have worked jointly with state and local health departments to investigate the outbreak, using epidemiologic and laboratory evidence to link cases to the contaminated moringa capsules. Traceback efforts identified organic moringa leaf powder as the vehicle for the earlier outbreak, though the precise contamination source remains unknown. Ambrosia Brands, LLC has provided a contact number, 914-768-1357, for consumers seeking information during business hours.

Federal officials continue to monitor the situation closely as the investigation proceeds. They have emphasized the importance of ongoing public health surveillance and consumer vigilance to prevent further illnesses linked to contaminated dietary supplements containing moringa leaf powder.

The recall affects select Zapp’s and Dirty brand potato chips produced by Utz Quality Foods, LLC, and sold nationwide, according to the U.S. Food and Drug Administration. The agency’s upgrade to a Class I recall—the FDA’s highest risk level—reflects a reasonable probability that exposure to the products could cause serious adverse health consequences or death, officials said. Package sizes range from 1.5-ounce bags to 8-ounce bags, with affected products carrying best-by dates from July 27 through August 31, 2026, according to FDA documentation.

The recall involves more than 600,000 bags of chips, including Zapp’s Bayou Blackened Ranch, Salt and Vinegar, and Big Cheezy varieties, as well as Dirty brand Salt and Vinegar, Maui Onion, and Sour Cream and Onion potato chips.

The potential contamination stems from a seasoning ingredient containing dry milk powder supplied by California Dairies Inc. and distributed through a third-party vendor, sources confirmed. Utz initiated the voluntary recall on April 28, 2026, after being informed by the supplier that the milk powder might be tainted with salmonella. Although batches of seasoning tested negative for salmonella before use, the recall proceeded as a precaution following the supplier-level recall, according to company and FDA statements. The FDA published a recall notice on May 4, 2026, identifying the seasoning as the source of concern.

No illnesses have been reported in connection with the recalled products as of the latest FDA updates, but the agency emphasized that salmonella infection can cause serious or sometimes fatal infections, particularly in young children, older adults, and people with weakened immune systems. Symptoms of salmonella infection include fever, nausea, vomiting, abdominal cramps, and diarrhea, according to FDA health guidance cited in reports.

The recall covers multiple flavors, sizes, and batch numbers, with detailed lists of affected products and codes available through the FDA’s recall notice and Utz’s consumer information materials. Consumers are advised not to eat the recalled chips and to discard any products they possess. Utz Customer Care can be contacted at 1-877-423-0149, Monday through Friday from 9 a.m. to 6 p.m. Eastern Time, for refunds or questions, according to company instructions. Retailers have been urged to remove recalled products from shelves to prevent further distribution.

The recall has been described in media reports as long-running, with varieties of Zapp’s and Dirty chips under recall since April 2026. The FDA’s elevation to a Class I recall on June 24, 2026, followed updated risk assessments based on the seasoning ingredient’s contamination potential. The agency’s classification signals the highest level of concern, indicating a reasonable probability that consumption of the affected products could result in serious health outcomes or death.

The recall does not include any other Utz products beyond the specified Zapp’s and Dirty brand potato chips. The company and FDA continue to monitor the situation closely, providing updated information as it becomes available. The public health response underscores the importance of ingredient-level recalls in preventing potential outbreaks, even when initial product testing does not detect contamination.

The outbreak spans seven counties: Monroe, Lenawee, Washtenaw, Wayne, Livingston, Shiawassee, and Jackson, officials said. The Michigan Department of Health and Human Services (MDHHS) confirmed it is working with local health departments in the region to investigate the surge and identify a common exposure.

Monroe County health officials reported 67 of the more than 150 cyclosporiasis cases identified in southeast Michigan since June 22, according to a statement from the Monroe County Health Department.

Cyclosporiasis is caused by the intestinal parasite Cyclospora cayetanensis, which is transmitted through food or water contaminated with feces, health officials explained. The parasite is not known to spread from person to person. The recent cluster in southeastern Michigan represents a sudden and large increase in cases, prompting coordinated epidemiologic investigations by state and local authorities.

Symptoms of cyclosporiasis typically appear two to 12 days after exposure and include frequent watery diarrhea, loss of appetite, weight loss, stomach cramps, bloating, nausea, fatigue, and low-grade fever, according to the Monroe County Health Department and MDHHS. Officials noted that symptoms may seem to resolve and then return, and untreated infections can last for weeks. While the illness is not considered life-threatening, it can significantly affect quality of life. Health departments recommend that individuals experiencing gastrointestinal symptoms seek medical evaluation for testing and treatment with antibiotics, which can effectively clear the infection. Maintaining hydration is also advised, especially during periods of high temperatures.

The outbreak coincides with a broader national context. CDC-linked data cited by CBS Detroit show more than 140 cyclosporiasis cases reported across the United States between May 1 and June 16, 2026. These cases occurred in 31 states, including Michigan, suggesting widespread exposure to contaminated produce or water sources, officials said. Recent U.S. outbreaks of cyclosporiasis have been linked repeatedly to fresh produce, particularly leafy greens, herbs, and other raw fruits and vegetables consumed during summer months.

MDHHS and local health authorities have not yet identified a specific food or water source responsible for the Michigan outbreak. Monroe County officials are currently investigating the source of the local cluster and emphasize that all produce should be thoroughly washed before consumption, whether served in restaurants or prepared at home. They also advise consumers to scrub firm fruits and vegetables with a clean brush, cut away damaged or bruised areas, and refrigerate cut, peeled, or cooked produce within two hours to reduce microbial risks.

Health officials reiterated that the parasite is contracted through the fecal-oral route and stressed that person-to-person transmission is unlikely. They cautioned residents to avoid consuming food or water that may be contaminated with feces and urged vigilance in food handling practices amid the ongoing investigation.

The MDHHS and Monroe County Health Department continue to monitor the situation closely and coordinate efforts to identify potential common exposures. Officials encourage individuals experiencing symptoms consistent with cyclosporiasis to contact healthcare providers promptly for testing and treatment. The investigation remains ongoing as public health authorities work to determine the outbreak’s source and prevent further cases.

Following the June 9 shakeup, Kennedy installed 13 new advisers to the Advisory Committee on Immunization Practices (ACIP), replacing the previous 17 members. Many of the new appointees were described as holding anti-vaccine views, fundamentally altering the committee’s composition, according to reporting by *The New York Times* and court documents. A federal judge ruled on March 16, 2026, that Kennedy’s appointments likely violated the Federal Advisory Committee Act (FACA) and invalidated the membership of the reconstituted ACIP.

The court’s order suspended all votes and decisions made by the committee over the prior year, including significant changes to the U.S. vaccination schedule, and blocked the committee from convening for a planned meeting, officials confirmed.

The court found that several policy changes implemented under Kennedy’s appointees were “arbitrary and capricious,” a legal standard indicating a lack of proper justification or adherence to required procedures. Among the invalidated decisions were the prohibition of thimerosal in flu vaccines, the discontinuation of the combined measles-mumps-rubella (MMR) and chickenpox vaccine recommendation, and the removal of the universal dose recommendation for the hepatitis vaccine. These changes, which affected about one-third of routine immunization guidelines, were made without following established advisory processes, the ruling stated.

Internal emails released by Democrats on the Senate Health, Education, Labor, and Pensions (HELP) Committee and reported by national media revealed political interference in vaccine policy following Kennedy’s confirmation as HHS Secretary. The communications showed that Kennedy and his top aides began altering vaccine recommendations and releasing materials to the public without review or input from CDC experts. One email from CDC official Nicole Coffin stated that Andrew Nixon of HHS requested that all campaign ad buys related to flu or vaccination encouragement be pulled from circulation, illustrating direct political pressure to halt pro-vaccine messaging.

Additional emails documented that Kennedy’s aides dispatched a disgraced researcher to search for evidence of a disproven autism-vaccine link without proper clearance or limits on access to sensitive data, bypassing routine scientific oversight. CDC staff reportedly “chafed at pressure” from Kennedy’s team as they navigated contentious vaccine decisions during President Trump’s second term, including policies related to seasonal flu vaccination and COVID-19, according to internal communications obtained by the Senate HELP Committee.

Beyond ACIP, Kennedy also removed at least half of the eight members serving on the Advisory Commission on Childhood Vaccines (ACCV), which advises on the federal vaccine injury compensation program. Among those dismissed were pediatricians Wendy Lane Burgert and Joshua Williams, as well as Veronica McN, a director of advocacy at a state university. Reporting indicated these removals mirrored Kennedy’s restructuring of ACIP, with midterm dismissals followed by plans to install new members aligned with Kennedy’s vaccine skepticism, suggesting a coordinated strategy to reshape both vaccine recommendation and compensation frameworks.

Kennedy justified his overhaul in a Wall Street Journal op-ed, asserting that federal vaccine advisers were “beholden to industry” and that the committee’s previous members had conflicts of interest. However, an investigation by *Science* found that ACIP members were subject to strict conflict-of-interest rules, including divestment from vaccine manufacturer stock and bans on advisory and consulting roles. The committee historically consisted of 15 voting members plus non-voting representatives who filed annual financial disclosures designed to minimize industry influence.

The changes prompted strong reactions from public health and industry groups. A biotech trade group memo described Kennedy as a “direct threat to public health,” reflecting industry concerns over his anti-vaccine stance and committee restructuring. Public health advocates, including Protect Our Care, characterized the leaked emails and committee changes as evidence of a “deadly anti-vax agenda” imposed over the objections of CDC leaders and career scientists.

The federal court’s ruling has delayed ACIP’s upcoming meeting, which had been scheduled to address alleged long-term effects following COVID-19 vaccination. An HHS representative confirmed the meeting’s postponement due to the invalidation of the committee’s membership. The ruling and email disclosures have fueled ongoing congressional, judicial, and public scrutiny of political influence in vaccine policymaking.

Kennedy’s overhaul of vaccine advisory bodies and the ensuing legal and political fallout mark a significant shift in U.S. vaccine policy governance. The court’s intervention underscores the importance of compliance with federal advisory regulations and established scientific review processes. Meanwhile, the Senate HELP Committee continues to review internal CDC communications as part of broader oversight into vaccine policy decisions during Kennedy’s tenure.

The affected products carry an expiration date of April 2027, which helps identify the production timeframe involved in the recall. The FDA classified the recall as Class II, indicating that exposure to the medication may cause temporary or medically reversible adverse health consequences, officials said.

The recalled chlorthalidone tablets were distributed nationwide in 100-count and 1,000-count bottles, with batch numbers RISA24001 and RISB24002, respectively, according to the FDA notice reviewed by multiple news outlets.

The reason for the recall was a failure to meet dissolution specifications, meaning the tablets did not dissolve properly during testing, which could affect the release rate of the active ingredient. This failure may result in the medication being less effective or delivering an inconsistent dose to patients, according to the FDA and health news reports. The issue stems from a manufacturing quality control problem rather than contamination or labeling errors, sources confirmed.

Inventia Healthcare Limited, the manufacturer based in India, initiated the recall, and Rising Pharma Holdings Inc., located in East Brunswick, New Jersey, distributed the product in the United States. The recall began on June 5, 2026, with the FDA issuing a public notice dated June 12, 2026, stating that the affected bottles were being withdrawn from distribution nationwide. The recall specifically targets certain lots and package sizes rather than all chlorthalidone products, according to FDA records.

Patients who have the recalled medication are advised to check their bottles for the specified batch numbers and package sizes and to contact their pharmacist or healthcare provider for guidance. The FDA and health officials cautioned patients not to stop taking chlorthalidone abruptly without consulting a healthcare professional. Some reports noted that patients might return the recalled medication to the place of purchase, subject to individual retailer policies, but the FDA has not issued detailed public instructions beyond the recall announcement.

Chlorthalidone is a commonly prescribed blood pressure medication used to treat hypertension. The nationwide recall affects more than 11,000 bottles, with the precise figure reported as 11,460. The recall has been covered widely by consumer and health news outlets, which consistently identified the product and the dissolution failure as the core issues. Other blood pressure medication recalls, such as those involving bisoprolol fumarate/hydrochlorothiazide or spironolactone, are unrelated and involve different classifications and concerns.

The FDA continues to monitor the recall and its impact, with the affected products being removed from the market as of June 2026. Further updates or instructions may be issued as the situation develops, according to agency officials.

As of June 26, 2026, the Pennsylvania Department of Health (DOH) confirmed 84 measles cases across six counties, with Lancaster County reporting the highest number at 41 cases, followed by Lebanon County with 20, Northumberland six, Berks and Dauphin two each, and York one, according to DOH records. The outbreak, described by health officials as ongoing, began in late April and has expanded from an initial cluster in Lebanon County to multiple counties in the state. Earlier reports in 2026 indicated 62 cases statewide, but the latest update reflects a significant increase, marking the largest measles surge in Pennsylvania since the early 1990s.

As of June 26, 2026, the Pennsylvania Department of Health (DOH) confirmed 84 measles cases across six counties, with Lancaster County reporting the highest number at 41 cases.

Health officials attributed the outbreak to the spread of the highly contagious measles virus, which is transmitted through respiratory droplets and airborne particles. The DOH has urged healthcare providers to promptly report suspected cases and adhere to testing protocols, including collecting throat or nasopharyngeal swabs, urine samples for rRT-PCR, and serum for measles IgM and IgG testing, as outlined in clinical advisory guidance issued in June. Providers are instructed to report suspected cases immediately by calling the DOH hotline at 877-724-3258 (877-PA-HEALTH).

The department also issued an exposure alert after a contagious out-of-state individual traveled through Adams, Clearfield, Lancaster, and York counties, advising residents who may have been exposed to monitor for symptoms such as fever, cough, runny nose, conjunctivitis, and rash, and to contact healthcare providers or the DOH hotline if symptoms develop. This travel-related exposure highlights the potential for measles to spread rapidly across counties, particularly in under-vaccinated populations.

Vaccination status among confirmed cases remains a concern. Earlier in 2026, DOH reported that none of the 32 measles patients identified at that time were known to be vaccinated, or their immunization status was unknown, suggesting vulnerability among under-immunized groups, especially school-age children. The department’s guidance stresses that routine measles-mumps-rubella (MMR) vaccination is the primary prevention tool, recommending two doses for children—first between 12 and 15 months of age and a second dose between 4 and 6 years before school entry. Adults born in or after 1957 are advised to have one or two documented MMR doses or laboratory evidence of immunity, with two doses recommended at least 28 days apart for those without documentation in outbreak settings.

In response to the outbreak, DOH and the Centers for Disease Control and Prevention (CDC) recommend additional doses beyond the routine schedule for high-risk adults and preschool children living in or traveling to affected areas. Post-exposure prophylaxis (PEP) protocols include administering the MMR vaccine within 72 hours of exposure or immune globulin within six days for individuals lacking evidence of immunity, according to clinical advisories. Health officials emphasize that exposed persons without immunity should be closely monitored for symptoms and seek immediate care if severe symptoms such as persistent fever or shortness of breath develop.

The 2026 outbreak represents a marked increase compared to previous years. DOH data show only nine confirmed measles cases statewide in 2025, distributed across Bucks, Erie, Montgomery, and Philadelphia counties. The current surge reflects a broader national trend, with the CDC reporting over 2,000 measles cases and more than 100 hospitalizations in the United States during 2026. Experts attribute this resurgence to clusters of under-vaccinated populations and increased travel-related spread, as exemplified by the recent out-of-state case passing through multiple Pennsylvania counties.

Public health efforts include heightened surveillance, clinician education, and coordinated responses among DOH, hospitals, and local health departments. The department has issued public alerts detailing county-level case counts and advising residents in affected areas to review vaccination records. Community vaccination and catch-up campaigns are underway to address under-immunization, particularly in schools where vaccination rates have declined significantly, according to local broadcast reports and health system advisories.

The Pennsylvania measles outbreak underscores ongoing challenges in controlling vaccine-preventable diseases amid shifting vaccination patterns. Health officials continue to monitor the situation closely and recommend that healthcare providers follow state and local guidance to contain transmission and protect vulnerable populations.